Tags

Type your tag names separated by a space and hit enter

The 2020 race towards SARS-CoV-2 specific vaccines.
Theranostics. 2021; 11(4):1690-1702.T

Abstract

The global outbreak of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted a requirement for two pronged clinical interventions such as development of effective vaccines and acute therapeutic options for medium-to-severe stages of "coronavirus disease 2019" (COVID-19). Effective vaccines, if successfully developed, have been emphasized to become the most effective strategy in the global fight against the COVID-19 pandemic. Basic research advances in biotechnology and genetic engineering have already provided excellent progress and groundbreaking new discoveries in the field of the coronavirus biology and its epidemiology. In particular, for the vaccine development the advances in characterization of a capsid structure and identification of its antigens that can become targets for new vaccines. The development of the experimental vaccines requires a plethora of molecular techniques as well as strict compliance with safety procedures. The research and clinical data integrity, cross-validation of the results, and appropriated studies from the perspective of efficacy and potently side effects have recently become a hotly discussed topic. In this review, we present an update on latest advances and progress in an ongoing race to develop 52 different vaccines against SARS-CoV-2. Our analysis is focused on registered clinical trials (current as of November 04, 2020) that fulfill the international safety and efficacy criteria in the vaccine development. The requirements as well as benefits and risks of diverse types of SARS-CoV-2 vaccines are discussed including those containing whole-virus and live-attenuated vaccines, subunit vaccines, mRNA vaccines, DNA vaccines, live vector vaccines, and also plant-based vaccine formulation containing coronavirus-like particle (VLP). The challenges associated with the vaccine development as well as its distribution, safety and long-term effectiveness have also been highlighted and discussed.

Authors+Show Affiliations

Chair and Department of Medical Microbiology, Poznań University of Medical Sciences, Wieniawskiego 3, 61-712 Poznań, Poland.Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants, Poznań, Poland.Division of Perinatology and Women's Disease, Poznań University of Medical Sciences, Poznań, Poland. Laboratory of Molecular Biology in Division of Perinatology and Women's Diseases, Poznań University of Medical Sciences, Poznań, Poland. Department of Pharmacology and Phytochemistry, Institute of Natural Fibres and Medicinal Plants, Poznań, Poland.Division of Perinatology and Women's Disease, Poznań University of Medical Sciences, Poznań, Poland. Division of Obstetrics and Gynecology, Tytus Chałubiński's Hospital, Zakopane, Poland.School of Science, RMIT University, Melbourne, VIC, Australia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33408775

Citation

Karpiński, Tomasz M., et al. "The 2020 Race Towards SARS-CoV-2 Specific Vaccines." Theranostics, vol. 11, no. 4, 2021, pp. 1690-1702.
Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, et al. The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics. 2021;11(4):1690-1702.
Karpiński, T. M., Ożarowski, M., Seremak-Mrozikiewicz, A., Wolski, H., & Wlodkowic, D. (2021). The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics, 11(4), 1690-1702. https://doi.org/10.7150/thno.53691
Karpiński TM, et al. The 2020 Race Towards SARS-CoV-2 Specific Vaccines. Theranostics. 2021;11(4):1690-1702. PubMed PMID: 33408775.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The 2020 race towards SARS-CoV-2 specific vaccines. AU - Karpiński,Tomasz M, AU - Ożarowski,Marcin, AU - Seremak-Mrozikiewicz,Agnieszka, AU - Wolski,Hubert, AU - Wlodkowic,Donald, Y1 - 2021/01/01/ PY - 2020/09/24/received PY - 2020/11/08/accepted PY - 2021/1/7/entrez PY - 2021/1/8/pubmed PY - 2021/1/8/medline KW - COVID-19 KW - SARS-CoV-2 KW - clinical trials KW - coronavirus disease 2019 KW - severe acute respiratory syndrome coronavirus 2 KW - vaccine SP - 1690 EP - 1702 JF - Theranostics JO - Theranostics VL - 11 IS - 4 N2 - The global outbreak of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted a requirement for two pronged clinical interventions such as development of effective vaccines and acute therapeutic options for medium-to-severe stages of "coronavirus disease 2019" (COVID-19). Effective vaccines, if successfully developed, have been emphasized to become the most effective strategy in the global fight against the COVID-19 pandemic. Basic research advances in biotechnology and genetic engineering have already provided excellent progress and groundbreaking new discoveries in the field of the coronavirus biology and its epidemiology. In particular, for the vaccine development the advances in characterization of a capsid structure and identification of its antigens that can become targets for new vaccines. The development of the experimental vaccines requires a plethora of molecular techniques as well as strict compliance with safety procedures. The research and clinical data integrity, cross-validation of the results, and appropriated studies from the perspective of efficacy and potently side effects have recently become a hotly discussed topic. In this review, we present an update on latest advances and progress in an ongoing race to develop 52 different vaccines against SARS-CoV-2. Our analysis is focused on registered clinical trials (current as of November 04, 2020) that fulfill the international safety and efficacy criteria in the vaccine development. The requirements as well as benefits and risks of diverse types of SARS-CoV-2 vaccines are discussed including those containing whole-virus and live-attenuated vaccines, subunit vaccines, mRNA vaccines, DNA vaccines, live vector vaccines, and also plant-based vaccine formulation containing coronavirus-like particle (VLP). The challenges associated with the vaccine development as well as its distribution, safety and long-term effectiveness have also been highlighted and discussed. SN - 1838-7640 UR - https://www.unboundmedicine.com/medline/citation/33408775/The_2020_race_towards_SARS_CoV_2_specific_vaccines_ L2 - https://www.thno.org/v11p1690.htm DB - PRIME DP - Unbound Medicine ER -